Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer

David Cella*, Lesley Fallowfield, Peter Barker, Jack Cuzick, Gershon Locker, Anthony Howell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

175 Scopus citations

Fingerprint Dive into the research topics of 'Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences